• Technology

    Technology

    Vector, target, indication getting the new combination to the clinics
  • About us

    About us

    Developing a single dose treatment for rheumatoid arthritis
  • Clinical program

    Clinical program

    10 years of development ready for clinical trial
  • Technology

    Technology

    Single dose treatment for chronic diseases
  • Technology

    Technology

    Vector, target, indication getting the new combination to the clinics
  • About us

    About us

    Developing a single dose treatment for rheumatoid arthritis
  • Clinical program

    Clinical program

    10 years of development getting ready for clinical trial
  • Technology

    Technology

    Single dose treatment for chronic diseases
  • HOME 767 310 02
  • HOME 767 310 01

About us

Arthrogen is an Amsterdam based biopharmaceutical company developing local gene therapy for inflammatory diseases, using viral mediated gene transfer.

Technology

The therapeutic vectors are derived from natural occurring adeno-associated viruses (AAV) that are not pathogenic in humans.

Clinical trials

The first target indication is in the field of rheumatic diseases. Arthrogen has completed GMP production of its lead product and is preparing the start of the first clinical trial.

Development

It is Arthrogen’s vision that new gene therapies will contribute to the improvement of health of patients and to the reduction of healthcare cost.

For professionals to learn more on our clinical development program, please follow this link….

For patients to learn more on our clinical development program, please follow this link….

Latest news

Arthrogen announces approval for Phase Ib study with gene therapy ART-I02 in patients with rheumatoid arthritis.

New publication: Empty Capsids and Macrophage Inhibition/Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic Mice....

Arthrogen CEO Robert Jan Lamers will be present at the janauary 9-12, 2017 JP Morgan Healthcare Conference. For meeting requests please use the contact form on our site or LinkedIn.

Arthrogen’s COO Janneke Meulenberg PhD. and CEO Robert Jan Lamers will be present at the Cell & Gene Therapy World 2017 in Miami, January 17-20 2017. On Thursday January 19 at 10.50-11.30am Janneke Meulenberg will present “AAV-mediated gene therapy for rheumatoid arthritis: toward clinical trials with ART-I02” at the Biotech Showcase Session. For meeting requests please use the Phacilitate meeting system, the contact form on www.arthrogen.nl or the Arthrogen LinkedIn page.

Latest publications

Empty Capsids and Macrophage Inhibition/Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic Mice....

Intra-articular etanercept treatment in inflammatory arthritis...

Preclinical Potency and Biodistribution Studies of an AAV 5 Vector...

Safety, Biodistribution, and Efficacy of an AAV-5 Vector Encoding Human Interferon-Beta (ART-I02)...